Who owns Bridgebio Oncology Therapeut (BBOT)?
21 US mutual funds and ETFs from 17 fund families reported a position in BBOT for the quarter ending 2026-06-30. Against their own report a quarter earlier, 3 raised shares, 11 opened a new position, 6 cut and 0 sold out.
Largest fund families
| Fund family | Funds | Share of fund-held shares |
|---|---|---|
| Vanguard Index Funds | 2 | 54.3% |
| Spdr Series Trust | 1 | 22.5% |
| Ishares Trust | 1 | 8.5% |
| T. Rowe Price Health Sciences Fund, Inc. | 1 | 6.2% |
| Royce Fund | 2 | 3.5% |
| Pacific Select Fund | 1 | 1.1% |
Tracked managers holding BBOT
None of the managers Prior Moves tracks on 13F reports BBOT in its latest filing.
Source: SEC Form N-PORT, which funds file about 60 days after quarter end, and the latest 13F filings. Share counts, not trades: a change can reflect fund inflows or outflows rather than a decision about BBOT. A record of holdings, not a forecast and not investment advice. See all owner pages or the forecast board for the names our model ranks.
Our model ranks every tracked manager’s likely next buys from 13F filings. Request the dataset sample with a work email.
The predicted next buys, fresh disclosures, and the week’s catalysts. One email a week. Honest numbers, never advice.